Evidence map›Paper›PMID 40574393›Full record

ReviewCurrent cancer drug targets2026

Unveiling the Therapeutic Potential of Compounds Carrying Mono- and Bis-Thiazole Nuclei with Distinct Heterocyclic Analogues for Addressing Cancer Challenges.

Thangavelu Saravanan, Chellappa Selvinthanuja, Selvaraj Jubie, M K Kathiravan, Ramasamy Thilagavathi, Veerasamy Ravichandran, Thangavelu Prabha

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thangavelu SaravananDepartment of Anaesthesiology, Government Medical College and Hospital, Pudukkottai, 622004, Tamil Nadu, India.
Chellappa SelvinthanujaDepartment of Pharmaceutical Chemistry, Nandha College of Pharmacy, The Tamil Nadu Dr. MGR Medical University, Chennai, Erode, 638052, Tamil Nadu, India.
Selvaraj JubieDepartment of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Tamil Nadu, India.
M K KathiravanDepartment of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, 603203, India.
Ramasamy ThilagavathiDepartment of Pharmaceutical Chemistry, Ennam College of Pharmacy, The Tamil Nadu Dr. MGR Medical University, Chennai, Coimbatore, 641032, Tamil Nadu, India.
Veerasamy RavichandranPharmaceutical Chemistry Unit, Faculty of Pharmacy, AIMST University, JalanBedong-Semeling, 08100, Malaysia.
Thangavelu PrabhaDepartment of Pharmaceutical Chemistry, Nandha College of Pharmacy, The Tamil Nadu Dr. MGR Medical University, Chennai, Erode, 638052, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe thiazole nucleus serves as a bioactive synthetic scaffold in drug design and discovery due to its diverse pharmacological activities. It was discovered that many types of thiazole derivatives, including those with one, two, or three substitutions, five- or six-membered heterocycles, fused rings, and thiazole-derived Schiff bases, hydrazinyl derivatives, amides, chalcones, and bis-thiazoles, can fight cancer. Thus, the structural diversity of thiazole nuclei makes it one of the significant areas of research in the pharmaceutical field.

objectiveWe would like to elaborate on the recent literature available on the antiproliferative property of molecules bearing 1,3-thiazole nuclei.

methodsThis review summarises the anticancer potency of thiazole derivatives collected from recently available scientific literature. We extracted the information from online databases like PubMed, Scopus, and Web of Science using relevant keywords from 2016 to the present. We discuss the current state of thiazole derivatives and highlight the most promising compounds. We also describe how they work and what their half-maximum inhibitory concentration (IC

resultsBased on our extensive literature review, we found that thiazole derivatives exhibit anticancer activity through their ability to induce apoptosis in cancer cells, mitochondrial membrane disruption by blocking signalling pathways such as Akt, NFkB, PI3K, and Src/Abl, and inhibition of proteins responsible for cell growth. Moreover, thiazole-protein interactions essential for cancer inhibition are predominantly regulated by hydrogen bonding, supported by the sulphur and nitrogen atoms in the thiazole molecule, which effectively interacts with the amino acids serine, tyrosine, and glutamine. π-π stacking and π-cation interactions involving aromatic amino acids such as tryptophan, tyrosine, and phenylalanine, along with hydrophobic effects and van der Waals forces, play a crucial role in thiazole-protein interactions. These interactions dictate binding affinity and efficacy, measured through thermodynamic characteristics such as Binding Constant (Kb), Dissociation Constant (Kb), and Gibbs free energy (ΔG). Comprehending these features is essential for the development of effective thiazole-based anticancer pharmaceuticals.

conclusionThis cumulative information is enough to give new ideas for the rational drug design of thiazole-based derivatives and could be pursued as a promising lead in the future for the management of cancer threats.

Indexed as

Antineoplastic AgentsHeterocyclic CompoundsNeoplasmsThiazolesAnimalsCell ProliferationDrug DesignHumansAntineoplastic AgentsHeterocyclic CompoundsThiazolesanticancerapoptosiscytotoxicityheterocyclic analoguephenylalanineThiazole derivatives

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.